[過去ログ]
【4565】そーせいG 508【薬事・食品衛生審議会医薬品第二部会(5/28)】 (664レス)
【4565】そーせいG 508【薬事・食品衛生審議会医薬品第二部会(5/28)】 http://hayabusa9.5ch.net/test/read.cgi/livemarket1/1590051012/
上
下
前
次
1-
新
通常表示
512バイト分割
レス栞
このスレッドは過去ログ倉庫に格納されています。
次スレ検索
歴削→次スレ
栞削→次スレ
過去ログメニュー
378: 山師さん@トレード中 [] 2020/05/29(金) 19:04:19 ID:kpWhJiVR0NIKU Treatment was associated with a reduction in both the number of immature immune suppressor cells as well as genetic markers of immune suppression in patient samples. These biomarker data validate the mechanism of action of MTL‑CEBPA in reducing immune suppression, which has been identified as a resistance mechanism of solid tumours to cancer treatment, including sorafenib. These encouraging Phase Ib data add to the previously published positive Phase I results in which four out of five patients experienced a durable, objective response to off-study sorafenib treatment after discontinuation of MTL‑CEBPA. As a single agent treatment, sorafenib is associated with a very low objective response rate. In a recent Phase III study, complete responses were observed in 1% of patients and partial responses were observed in 6% of patients based on RECIST 1.1 criteria in 372 patients1. The poster will be made available on the “Publications” page of MiNA’s website. ASCO Presentation information: Title: Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) Abstract no: 4601 Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Date / time: Friday, May 29, 2020 / 8:00 am Eastern Time http://hayabusa9.5ch.net/test/read.cgi/livemarket1/1590051012/378
メモ帳
(0/65535文字)
上
下
前
次
1-
新
書
関
写
板
覧
索
設
栞
歴
あと 286 レスあります
スレ情報
赤レス抽出
画像レス抽出
歴の未読スレ
AAサムネイル
Google検索
Wikipedia
ぬこの手
ぬこTOP
0.035s